Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 15 , ISSUE 4 ( July-August, 2023 ) > List of Articles

Original Article

The Effect of Transdermal Testosterone Gel Pretreatment on IVF Outcomes in Patients with Poor Ovarian Reserve

Nidhi Sharma, Kanad D Nayar

Keywords : Poor ovarian reserve, POSEIDON classification, Testosterone gel

Citation Information : Sharma N, Nayar KD. The Effect of Transdermal Testosterone Gel Pretreatment on IVF Outcomes in Patients with Poor Ovarian Reserve. J South Asian Feder Obs Gynae 2023; 15 (4):419-423.

DOI: 10.5005/jp-journals-10006-2278

License: CC BY-NC 4.0

Published Online: 16-09-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Aim: To investigate the effect of pretreatment with testosterone gel on IVF outcomes in patients with poor ovarian reserve. Materials and methods: In this prospective, single-blinded, randomized controlled trial, 87 patients, young or old (< or ≥35 years) with diminished ovarian reserve (DOR) (AFC ≤5, AMH ≤1.2 ng/mL) undergoing IVF treatment were enrolled and randomly divided into two groups. In the treatment group, 41 patients received pretreatment with testosterone gel (12.5 mg/day; from the 6th day of the previous menstrual cycle to 2nd day of stimulated cycle), and in the control group, 46 patients received lubricant gel. Results: Total number of oocytes retrieved (4.05 vs 2.72; p < 0.05) was significantly more in the treatment group than in the control group. Similarly, the number of grade A embryos (2.78 vs 1.96; p < 0.05) was significantly greater in the TTG group. The clinical pregnancy rate per patient was higher in the TTG group (37% vs 29.3%) but the difference was not statistically significant. Conclusion: Testosterone gel application before stimulation helps in reducing the dose and duration of gonadotrophins and to increase the number of oocytes retrieved and the quality of embryos formed in DOR patients. Clinical significance: Pretreatment with androgen before ovarian stimulation can be offered to patients with poor ovarian reserve.

  1. Gardner DK, Weissman A, Howles CM, et al. Textbook of Assisted Reproductive Techniques. 5th Edition. Florida, USA: CRC press, 2018.
  2. Walters KA, Handelsman DJ. Role of androgens in the ovary. Mol Cell Endocrinol 2018;465:36–47. DOI: 10.1016/j.mce.2017.06.026.
  3. Gervásio CG, Bernuci MP, Silva-de-Sá MF, et al. The role of androgen hormones in early follicular development. ISRN Obstet Gynecol 2014; 2014:818010. DOI: 10.1155/2014/818010.
  4. Humaidan P, Alviggi C, Fischer R, et al. The novel POSEIDON stratification of ‘Low prognosis patients in Assisted Reproductive Technology’ and its proposed marker of successful outcome. F1000Res. 2016;5:2911. DOI: 10.12688/f1000research.10382.1.
  5. Conforti A, Esteves SC, Picarelli S, et al. Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology: The POSEIDON concept. Panminerva Med 2019;61:24–29. DOI: 10.23736/S0031-0808.18.03511-5.
  6. Papathanasiou A, Searle BJ, King NM, et al. Trends in ‘poor responder’ research: lessons learned from RCTs in assisted conception. Hum Reprod Update 2016;22(3):306–319. DOI: 10.1093/humupd/dmw001.
  7. Haahr T, Dosouto C, Alviggi C, et al. Management strategies for POSEIDON Groups 3 and 4. Front Endocrinol 2019;10:614. DOI: 10.3389/fendo.2019.00614.
  8. Esteves SC, Carvalho JC, Bento FC, et al. A novel predictive model to estimate the number of mature oocytes required for obtaining at least one euploid blastocyst for transfer in couples undergoing in vitro fertilization/intracytoplasmic sperm injection: the ART Calculator. Front Endocrinol 2019;10:99. DOI: 10.3389/fendo.2019.00099.
  9. Noventa M, Vitagliano A, Andrisani A, et al. Testosterone therapy for women with poor ovarian response undergoing IVF: a meta-analysis of randomized controlled trials. Journal of assisted reproduction and genetics 2019;36(4):673–683. DOI: 10.1007/s10815-018-1383-2.
  10. Doan HT, Quan LH, Nguyen TT. The effectiveness of transdermal testosterone gel 1% (androgel) for poor responders undergoing in vitro fertilization. Gynecol Endocrinol 2017;33(12):977–979. DOI: 10.1080/09513590.2017.1332586.
  11. Saharkhiz N, Zademodares S, Salehpour S, et al. The effect of testosterone gel on fertility outcomes in women with a poor response in in vitro fertilization cycles: A pilot randomized clinical trial. J Res Med Sci 2018;23:3. DOI: 10.4103/jrms.JRMS_864_17.
  12. Kim CH, Howles CM, Lee HA. The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertil Steril 2011;95(2):679–683. DOI: 10.1016/j.fertnstert.2010.07.1077.
  13. Jeve YB, Bhandari HM. Effective treatment protocol for poor ovarian response: A systematic review and meta-analysis. J Hum Reprod Sci 2016;9(2):70–81. DOI: 10.4103/0974-1208.183515.
  14. Bosdou JK, Venetis CA, Dafopoulos K, et al. Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial. Hum Reprod 2016;31(5):977–985. DOI: 10.1093/humrep/dew028.
  15. Vishwakarma P, Joy I, Varma TR. Role of testosterone pretreatment in poor ovarian responders undergoing in vitro fertilization/intracytoplasmic injection in comparison with growth hormone. IVF Lite 2016;3:90–97. DOI: 10.4103/2348-2907.204667.
  16. Kim CH, Ahn JW, Moon JW, et al. Ovarian features after 2 weeks, 3 weeks and 4 weeks transdermal testosterone gel treatment and their associated effect on IVF outcomes in poor responders. Dev Reprod 2014;18(3):145–152. DOI: 10.12717/DR.2014.18.3.145.
  17. Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol 2016;5(6):834–843. DOI: 10.21037/tau.2016.07.10.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.